Valeant Pharmaceuticals' business model involved manipulating accounting (changing non-GAAP EBITDA calculations year-to-year), creating fraudulent networks of online pharmacies, and manipulating drug pricing—all of which were discoverable through forensic analysis despite management's public claims about integrity and drug reformulation.